No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Celltrion Launches US Pediatric High Concentration Adalimumab Biosimilar
On 28 March 2024, the Korea IT Times reported the US launch of Celltrion’s pediatric 20mg Yuflyma®, biosimilar to AbbVie’s Humira® (adalimumab), for the treatment of pediatric autoimmune disease. Three Yuflyma® dosage forms are now available in the US, with an 80mg...